Brief: Greenwich Lifesciences Inc - Initiates New Us Clinical Sites For Flamingo-01 Phase Iii Trial
19/03/2026 11:51
March 19 (Reuters) - Greenwich Lifesciences Inc GLSI.O: GREENWICH LIFESCIENCES INC - INITIATES NEW US CLINICAL SITES FOR FLAMINGO-01 PHASE III TRIAL GREENWICH LIFESCIENCES INC - FLAMINGO-01 PHASE III TRIAL ACTIVATED AT CITY OF HOPE NETWORK SITES GREENWICH LIFESCIENCES INC - FLAMINGO-01 TRIAL SITES COULD INCREASE TO 190-200 FROM CURRENT 160 Source text: ID:nGNX766qnf Further company coverage: GLSI.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio